 8/10 Excellent --- eutils.ncbi.nlm.nih.gov http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0UmU1tY94fd9W82MB
| NCBI: db=PubMed; Term=0149-5992 ... |
Wednesday, August 06, 2008 --- 154 days ago http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&a
| Related Articles Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled with Oral Agents. Diabetes Care. 2008 Aug 4; Authors: Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss A, Kramer D, Petrucci R, Yu W, Levy B, Objective- This double-blind, placebo-controlled, randomized, multicenter, parallel-group study compared the efficacy, safety, and tolerability of Technosphere(R) Insulin (TI) with Technosphere(R) powder (TP) as placebo in insulin-naïve type 2 diabetic patients suboptimally controlled with oral antidiabetic agents. Research design and methods- Patients (n=126) were randomized to 12 weeks of therapy with TI or TP following lifestyle education on nutrition, exercise, and instructions on inhaler use. The primary efficacy outcome was change in glycosylated hemoglobin A1C (A1C) from baseline to study end, and the secondary efficacy outcome was area under the curve for postprandial glucose levels during a meal test at treatment weeks 4, 8, and 12. Results- A1C reduction from a mean baseline of 7.9% was greater with TI than with TP (-0.72% vs. -0.30%; P=0.003). Postprandial glucose excursions were reduced by 56% with TI compared with baseline, and maximal postprandial glucose levels were reduced by 43% compared with TP. Incidences of hypoglycemia, hyperglycemia, cough, and other adverse events were low in both groups. B ... |
|
|
Anytime
